NeuroBo Pharmaceuticals Q2 EPS $(1.85) Misses $(1.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported a Q2 EPS of $(1.85), significantly missing the analyst consensus estimate of $(1.12) by 65.18%. This represents a 12233.33% decrease compared to the same period last year.
August 14, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NeuroBo Pharmaceuticals reported a Q2 EPS of $(1.85), missing the analyst consensus estimate of $(1.12) by 65.18%. This significant miss and the drastic year-over-year decrease in EPS are likely to negatively impact the stock price in the short term.
The significant miss on EPS estimates and the drastic year-over-year decrease in EPS are strong negative indicators for investors. Such results typically lead to a decline in stock price as they reflect poorly on the company's financial health and performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100